Journal article
Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies
Abstract
The clinical effect of prednisone in metastatic castration-resistant prostate cancer (mCRPC) is unknown. We performed a pooled analysis of control arms of randomized controlled trials that had or had not administered single-agent prednisone. Randomized controlled trials with a control arm that included single-agent placebo (or no anticancer therapy) or single-agent prednisone (with or without placebo) were eligible for analysis. Patients …
Authors
Ghatalia P; Pond GR; Templeton AJ; Sonpavde G
Journal
Clinical Genitourinary Cancer, Vol. 16, No. 2, pp. e277–e287
Publisher
Elsevier
Publication Date
April 2018
DOI
10.1016/j.clgc.2017.12.006
ISSN
1558-7673